Compare Hyatt Hotels Corporation (H) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Incyte Corporation — how do they compare? Hyatt Hotels Corporation trades at $189 (market cap $17.85B), while Incyte Corporation trades at $115.7 (market cap $23.11B). The key difference: Incyte Corporation is the larger of the two by market cap, and Hyatt Hotels Corporation pays a 0.32% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| H | INCY | |
|---|---|---|
Market Cap | $17.85B | $23.11B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $118.52 |
52-Week Low | $135.01 | $67.38 |
Enterprise Value | $21.69B | $19.13B |
Dividend Yield | 0.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
